These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14941809)

  • 1. [The first step to transfuse man with leukocytes and platelets labeled with radiophosphorus].
    JULLIARD J; MAUPIN B; LOVERDO A; BERNARD J; COLVEZ P; LECOMTE M; DUGAS J; ARDRY R; HENAFF F; PERROT F; ROBERT MP; THEILLEUX R
    Presse Med (1893); 1952 Apr; 60(24):518-20. PubMed ID: 14941809
    [No Abstract]   [Full Text] [Related]  

  • 2. [Transfusion of radiophosphorus labeled human leucocytes and blood platelets into the rabbit].
    JULLIARD J; MAUPIN B; CHARY R; THEILLEUX R; NAU P; LOVERDO A
    C R Seances Soc Biol Fil; 1952 Feb; 146(3-4):211-4. PubMed ID: 14945123
    [No Abstract]   [Full Text] [Related]  

  • 3. [THE INFLUENCE OF TRANSFUSION ON ISOANTIBODY FORMATION].
    ASZODI L; STENSZKY V; SZABO G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1963; 80():268-72. PubMed ID: 14045433
    [No Abstract]   [Full Text] [Related]  

  • 4. [Transfusion of blood platelets labeled with Cr51 in the hamster. Study in vivo].
    FICHERA C
    Boll Soc Ital Biol Sper; 1962 Dec; 38():1277-80. PubMed ID: 13945017
    [No Abstract]   [Full Text] [Related]  

  • 5. [Incorporation of Cr51 into the organs of hamsters after transfusion with labeled blood platelets].
    FICHERA C
    Boll Soc Ital Biol Sper; 1962 Dec; 38():1280-3. PubMed ID: 13945018
    [No Abstract]   [Full Text] [Related]  

  • 6. [Preparation of leukocyte-depleted thrombocyte concentrate: in-vitro testing of a new filtration system (PL 100)].
    Böck M; Himmelsbach S; Gudden A; Greither L; Mempel W
    Infusionstherapie; 1991 Feb; 18(1):30-2. PubMed ID: 2030050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in non-MHC restricted cytotoxic activities of human peripheral blood lymphocytes after transfusion with allogeneic leukocytes or platelets possessing class I and/or class II MHC molecules.
    Pócsik E; Mihalik R; Réti M; Gyódi E; Pálóczi K; Mayer K; Kassai M; Herold M; Huber C; Petrányi GG
    Immunobiology; 1990 Dec; 182(1):22-31. PubMed ID: 1983002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative assessment of platelet morphology by light scattering: a potential method for the evaluation of platelets for transfusion.
    Fratantoni JC; Poindexter BJ; Bonner RF
    J Lab Clin Med; 1984 Apr; 103(4):620-31. PubMed ID: 6699477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of leukodepletion on allogeneic donor platelet survival and refractoriness in an animal model.
    Blajchman MA
    Semin Hematol; 1991 Jul; 28(3 Suppl 5):14-7. PubMed ID: 1925637
    [No Abstract]   [Full Text] [Related]  

  • 10. Platelet life span as measured by transfusion of isotopically labeled platelets into rats.
    ODELL TT; TAUSCHE FG; FURTH J
    Acta Haematol; 1955 Jan; 13(1):45-52. PubMed ID: 14361090
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunological support of component blood transfusion therapy].
    Shablin VN; Serova LD; Abdulkadyrov KM; Mel'nikova VN
    Probl Gematol Pereliv Krovi; 1978 Aug; 23(8):3-7. PubMed ID: 683985
    [No Abstract]   [Full Text] [Related]  

  • 12. [Transfusion of leukocytes and platelets in the treatment of acute leukemia].
    Baklaja R; Stajić M; Banicević B; Jancić M; Cvetković V; Maslovarić S; Susaković N; Andelić M; Stefanović S
    Bilt Hematol Transfuz; 1978; 6(3):31-8. PubMed ID: 295220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet transfusions and administration of platelet derivatives in man. I. Evaluation of laboratory technics used for prognostic purposes.
    RACCUGLIA G; BETHELL FH
    Am J Clin Pathol; 1960 Dec; 34():495-512. PubMed ID: 13738893
    [No Abstract]   [Full Text] [Related]  

  • 14. [Formation of anti-leukocyte antibody and anti-platelet antibody and its effects on blood component transfusion].
    Shimoyama M; Minato K; Ideura Y; Kimura K
    Nihon Rinsho; 1977 Dec; 35(12):4146-54. PubMed ID: 342757
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelet transfusions a constantly evolving therapy.
    Slichter SJ
    Thromb Haemost; 1991 Jul; 66(1):178-88. PubMed ID: 1926048
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
    Eernisse JG; Brand A
    Exp Hematol; 1981 Jan; 9(1):77-83. PubMed ID: 7238644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloimmunization by leukocyte-rich or leukocyte-poor random single donor platelets.
    Gmür J; Burger J; Sauter C; Oelz O; Frick PG
    Prog Clin Biol Res; 1990; 337():45-8. PubMed ID: 2191337
    [No Abstract]   [Full Text] [Related]  

  • 18. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transfusion of human blood platelets with a note on the transfusion of granulocytes.
    HIRSCH EO; GARDNER FH
    J Lab Clin Med; 1952 Apr; 39(4):556-69. PubMed ID: 14917920
    [No Abstract]   [Full Text] [Related]  

  • 20. The transfusion of human blood platelets.
    HIRSCH EO
    N Y State J Med; 1953 Mar; 53(5):549-50. PubMed ID: 13037055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.